Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy

– In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline® Depot
(lanreotide) redesigned pre-filled syringe compared with the syringe for long-acting release octreotide
–
CAMBRIDGE, Mass. March 11, 2020 — Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext:
IPN; ADR: IPSEY) today announced the presentation of the PRESTO study by ENETS, and its
simultaneous publication in the peer-reviewed journal, Advances in Therapy.
1
PRESTO was a multi-national, multi-center, prospective, non-interventional, simulated-use study that
enrolled 90 nurses with ≥ 2 years’ experience injecting with the lanreotide (Somatuline® Depot)
syringe and/or the syringe for long-acting release octreotide. The primary objective of the PRESTO
study was to assess nurse preference between the redesigned Somatuline® Depot syringe and the
syringe for long-acting release octreotide after performing injections into injection pads.
The PRESTO study incorporated an anonymous, web-based questionnaire, where nurses reported
their overall preference. Virtually all participants (97.8%) expressed a preference (85.6% “strong”,
12.2% “slight”) for the redesigned Somatuline® Depot syringe versus the octreotide syringe.
Comparative safety and efficacy between Somatuline® Depot and octreotide were not evaluated in
this study.
“The experiences, attitudes and knowledge of both patients and healthcare practitioners, including
nurses, was essential in the redesign of the syringe,” said Daphne T. Adelman, Clinical Nurse
Specialist from Northwestern University in Chicago, and a lead author on the PRESTO study. “In the
absence of head-to-head trials, these data give healthcare professionals important insights. The
ENETS poster presentation and the Advances in Therapy publication of the PRESTO study provide
further details on the benefits of the redesigned syringe.”
Indications for Somatuline® Depot include the treatment of adult patients with unresectable, well- or
moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine
tumors (GEP-NETs) to improve progression-free survival; treatment of adults with carcinoid
syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy;
and the long-term treatment of patients with acromegaly who have had an inadequate response to
surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Please see
Important Safety Information below and accompanying full Prescribing Information.
“The redesigned Somatuline® Depot syringe was developed based on feedback from physicians,
nurses and patients;
2 and the PRESTO study, for the first time, demonstrates the nurses’ preference
for it versus the octreotide syringe,” said Tamer Garawin, M.D., Vice President, Medical Affairs
Oncology at Ipsen Biopharmaceuticals. “PRESTO is an example of how Ipsen continues our
commitment to partnering with patients and healthcare providers, especially nurses, who play a key
role in the management of GEP-NETs and acromegaly.”
In addition to the PRESTO study, Ipsen had a record 12 abstracts accepted by ENETS.
PRESS RELEASE
*ABOUT PRESTO
PRESTO was a randomized, multinational, multicenter, noninterventional, simulated-use study
involving nurses (n=90) with experience injecting with the Somatuline® Depot syringe and/or the
syringe for long-acting release octreotide. The primary objective of this study was to assess
preferences of nurses between injecting with the Somatuline® Depot syringe and the syringe for longacting release octreotide. Nurses attended a single testing session, during which they injected
injection pads with each type of syringe twice before reporting their preferences. Data were collected
using an anonymous, self-administered, web-based questionnaire. Limitations of this study included
the need for a change in injection pad after 10 injection sessions due to clogging issues which
resulted in two separate cohorts, and that the injections performed were simulated. There were
imbalances noted in sociodemographics and clinical setting of nurses which potentially introduces
biased reporting of preferences. Another limitation was that some nurses were recruited from the
CRO (Contract Research Organization) network organizing the study. This study was not designed to
evaluate the efficacy or safety of Somatuline® Depot or long-acting release octreotide and no
assessment of efficacy or safety should be interpreted based on this study.
ABOUT NETs
A neuroendocrine tumor (NET) begins in the hormone-producing cells of the body’s neuroendocrine
system, which is made of cells that are a combination of hormone-producing endocrine cells and nerve
cells.3 NETs are a group of uncommon tumors occurring in both men and women aged 50 to 60 years
old although they can affect anyone of any age.3
The three main areas where NETs are found in the body are the gastrointestinal tract, the pancreas
and the lungs.3

Gastrointestinal NETs (GEP-NETs) are found in the gastrointestinal tract or digestive system
and are the most common type of NETs.3
Pancreatic NETs (pNETs) are formed in the islet cells of the pancreas and include several
uncommon types of NETs.3
Lung NETs are less common than other types, accounting for about one quarter of NETs.3
The symptoms of NETs are often not distinct and difficult to identify, and average time from initial onset
of symptoms to proper diagnosis can take more than 5 years.4 Although NETs affect only a small
percentage of the general population at any one time, the number of people being newly diagnosed
with NETs overall is believed to be rising.3 This is mainly due to increased awareness of the condition
and diagnostic testing.3 NETs are now the fastest growing class of cancers worldwide, accounting for
around 2% of all cancers at any time.3
ABOUT ACROMEGALY
Acromegaly is an uncommon hormonal or endocrine disorder with slowly developing, but eventually
distinct clinical symptoms.5 In the U.S., approximately 3,500 new cases of acromegaly are diagnosed
each year.6
It is usually caused by having too much growth hormone in the body which, over time, results in some
characteristic symptoms and signs, such as heavy or prominent facial features with a prominent jaw
line and enlarged hands and feet.5
What is SOMATULINE® DEPOT (lanreotide) Injection?
SOMATULINE DEPOT is a prescription medicine used in adults for:
the long-term treatment of people with acromegaly when surgery or radiotherapy have not
worked well enough or a patient is unable to have surgery or radiotherapy;
the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal
tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin
medicine.
It is not known if SOMATULINE DEPOT is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not take SOMATULINE DEPOT if you are allergic to lanreotide.
SOMATULINE DEPOT may cause serious side effects, including:
o Gallstones
o Changes to your blood sugar (high or low blood sugar),
o Slow heart rate,
o High blood pressure, and
o Changes in thyroid function in acromegaly patients.
Tell your healthcare provider (HCP) if you have any of the following symptoms:
o Symptoms of gallstones may include sudden pain in your upper right stomach area
(abdomen), sudden pain in your right shoulder or between your shoulder blades,
yellowing of your skin and whites of your eyes, fever with chills, and nausea.
o Symptoms of high blood sugar may include increased thirst, increased appetite,
nausea, weakness or tiredness, urinating more than normal, and fruity smelling
breath.
o Symptoms of low blood sugar may include dizziness or lightheadedness, sweating,
confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat,
irritability or mood changes, and hunger.
o Symptoms of slow heart rate may include dizziness or lightheadedness, fainting or
near-fainting, chest pain, shortness of breath, confusion or memory problems, and
weakness or extreme tiredness.
o SOMATULINE DEPOT can cause the thyroid gland to not make enough thyroid
hormone in people with acromegaly. Symptoms of low thyroid levels may include
fatigue, weight gain, puffy face, being cold all the time, constipation, dry skin, thinning
or dry hair, decreased sweating, and depression.
The most common side effects of SOMATULINE DEPOT in people with:
o Acromegaly: diarrhea; stomach (abdominal) pain; nausea; and pain, itching, or a
lump at the injection site
o GEP-NETs: stomach area (abdominal) pain; muscle and joint aches; vomiting;
headache; pain, itching or a lump at the injection site
o Carcinoid syndrome: headache, dizziness, muscle spasm; side effects were
generally similar to those commonly seen with GEP-NETs
SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate
machinery.
Tell your HCP right away if you have signs of an allergic reaction after receiving
SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems;
fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or
redness; rash; or hives.
Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions
including if you: have diabetes; have gallbladder, heart, thyroid, kidney or liver problems;
are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not
known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You
should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last
dose. SOMATULINE DEPOT may affect your ability to become pregnant.
Tell your HCP about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements. SOMATULINE DEPOT and other
medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the
way other medicines work, and other medicines may affect how SOMATULINE DEPOT
works. Your dose of SOMATULINE DEPOT or your other medications may need to be
changed. If you have diabetes, your HCP may change your dose of diabetes medication
when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT
is changed.
Especially tell your HCP if you take:
o Insulin or other diabetes medicines,
o A cyclosporine (Gengraf, Neoral, or Sandimmune), or
o Medicines that lower your heart rate, such as beta blockers.
Know the medicines you take. Keep a list of them to show your HCP when you get a new
medicine.
Tell your HCP if you have any side effect that bothers you or that does not go away. These are not all
the possible side effects of SOMATULINE DEPOT. For more information, ask your HCP.
To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-
463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
It is not known if SOMATULINE DEPOT is safe and effective in children.
Please see full Prescribing Information, including Patient Information
About Ipsen in North America
Ipsen (Euronext: IPN; ADR: IPSEY) is a global biopharmaceutical company focused on innovation
and specialty care. The company develops and commercializes innovative medicines in three key
therapeutic areas – Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources,
investments and energy on discovering, developing and commercializing new therapeutic options to
provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen’s North
American operations are located in Cambridge, Massachusetts, one of the company’s three global
hubs. Based in the heart of Kendall Square, our fully integrated biopharmaceutical business includes
Commercial, Research & Development, Manufacturing, and Global External Innovation and
Partnering. Combined with our Canadian headquarters in Mississauga, Ontario, and other locations,
Ipsen employs approximately 600 people in North America. For more information please visit
www.ipsenus.com or www.ipsen.ca Connect with us on Twitter and LinkedIn.
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s
management strategy, current views and assumptions. The statements here reflect the outcome of a
small simulated study and it is uncertain whether the outcome can be extrapolated to the general
nurse or healthcare population. Such statements involve known and unknown risks and uncertainties
that may cause actual results, performance or events to differ materially from those anticipated
herein. All of the above risks could affect the Group’s future ability to achieve its financial targets,
which were set assuming reasonable macroeconomic conditions based on the information available
today. Use of the words “believes”, “anticipates” and “expects” and similar expressions are intended
to identify forward-looking statements, including the Group’s expectations regarding future events,
including regulatory filings and determinations. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and assumptions regarded as
reasonable by the Group. These targets depend on conditions or facts likely to happen in the future,
and not exclusively on historical data. Actual results may depart significantly from these targets given
the occurrence of certain risks and uncertainties, notably the fact that a promising product in early
development phase or clinical trial may end up never being launched on the market or reaching its
commercial targets, notably for regulatory or competition reasons. The Group must face or might face
competition from generic products that might translate into a loss of market share. Furthermore, the
Research and Development process involves several stages each of which involves the substantial
risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards
to a product in which it has invested significant sums. Therefore, the Group cannot be certain that
favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials,
or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the
product concerned. There can be no guarantees a product will receive the necessary regulatory
approvals or that the product will prove to be commercially successful. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those
set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care
legislation; global trends toward health care cost containment; technological advances, new products
and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approval; the Group’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the Group’s patents and other protections for innovative products;
and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also
depends on third parties to develop and market some of its products which could potentially generate
substantial royalties; these partners could behave in such ways which could cause damage to the
Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their
obligations. It might be unable to obtain any benefit from those agreements. A default by any of the
Group’s partners could generate lower revenues than expected. Such situations could have a
negative impact on the Group’s business, financial position or performance. The Group expressly
disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or
estimates contained in this press release to reflect any change in events, conditions, assumptions or
circumstances on which any such statements are based, unless so required by applicable law. The
Group’s business is subject to the risk factors outlined in its registration documents filed with the
French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and
the reader is advised to refer to the Group’s 2018 Registration Document available on its website
(www.ipsen.com).
For further information:
Maryann Quinn
Director, Product Communications
857-529-1151
Maryann.quinn@ipsen.com
References

Adelman D et al. Adv Ther 2020 Mar 11. doi:10.1007/s12325-020-01255-8
Data on File
Oronsky, B, Ma, PC, Morgensztern, D & Carter, CA et al (2017). Nothing But NET: A Review of
Neuroendocrine Tumors and Carcinomas. Neoplasia. 19(12):991-1002.
Modlin, IM, Moss, SF, Chung, DC, Jensen, RT, & Snyderwine E (2008). Priorities for Improving
the Management of Gastroenteropancreatice Neuroendocrine Tumors. Journal of the National
Cancer Institute, 100, 1282-1289.
Acromunity: Acromegaly information and support. Available at: https://www.acromunity.com
[Accessed March 2019].
Burton et al (2016). Incidence and prevalence of acromegaly in a large US health plan. Database.
Pituitary.19:262–267.

#

SOMATULINE DEPOT is a registered trademark of IPSEN PHARMA S.A.S.
All other trademarks and registered trademarks are property of their respective owners.
© 2020 Ipsen Biopharmaceuticals, Inc.
March 2020
SMD-US-003889